For people with certain types of DLBCL who have received at least 2 prior courses of therapy,
For people with certain types of DLBCL who have received at least 2 prior courses of therapy,
DLBCL=diffuse large B-cell lymphoma.
Find valuable information about DLBCL and what it means to have relapsed or refractory DLBCL
Discover how this bispecific antibody treatment can help people with certain types of DLBCL
What you need to know as you begin your COLUMVI treatment journey
B cell
A type of white blood cell that makes antibodies. B cells are part of the immune system and develop from stem cells in the bone marrow. DLBCL is a type of B-cell lymphoma.
Bispecific antibody
Bispecific antibodies are designed to target 2 different sites on different cells or the same cell. For example, a bispecific antibody binding to 2 different cells is thought to bring the cells together, such as an immune cell and cancer cell.
Complete remission
Also called complete response—the disappearance of all signs of cancer in response to treatment. This does not mean the cancer has been cured.
Continuous treatment
Designed for use until disease worsens or unacceptable side effects occur.
Cycle
A period of treatment followed by a period of rest (no treatment) that is repeated on a regular schedule.
Cytokine release syndrome (CRS)
A side effect when your immune system responds too strongly by rapidly releasing a large amount of substances known as cytokines. It may cause fever, nausea, or other symptoms.
Diffuse large B-cell lymphoma (DLBCL)
The most common type of B-cell non-Hodgkin lymphoma (NHL). DLBCL is marked by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other tissues and organs.
Fixed-duration therapy
A treatment that is designed to be given for a pre-specified number of cycles.
Large B-cell lymphoma (LBCL)
The most common type of B-cell non-Hodgkin lymphoma (NHL). With NHL, abnormal lymphocytes build up in the lymph nodes, bone marrow, and spleen. DLBCL is a subtype of LBCL.
Non-Hodgkin lymphoma
A type of cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. DLBCL is a type of non-Hodgkin lymphoma.
Overall response
A partial or complete remission.
Partial remission
Also called partial response—some measurable decrease in size of the cancer.
Phase 1/2 clinical trial
The first 2 phases of a clinical trial program that studies an investigational treatment.
Refractory
A term used to describe disease that has not responded to previous treatment.
Relapsed
A term used to describe disease that has returned after responding to previous treatment.
Remission
A term used to describe a response to treatment.
Step-up dose
A smaller dose of COLUMVI that you receive on Day 8 and Day 15 of your first cycle of treatment.
T cell
A type of white blood cell. T cells are part of the immune system, helping to protect the body from infection and may also help fight cancer. A subset, cytotoxic T cells, binds to and kills infected cells and cancer cells.
Complete response
Also called complete remission—the disappearance of all signs of cancer in response to treatment. This does not mean the cancer has been cured.
Partial response
A decrease in the size of a tumor or in the extent of cancer in the body in response to treatment. Also called partial remission.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.